金安國紀(002636.SZ):年產6000萬米電子級玻纖布擴建項目預計在2022年下半年投產
格隆匯9月24日丨金安國紀(002636.SZ)公佈,此前披露,公司於2018年9月17日召開了第四屆董事會第四次會議,審議通過了《關於子公司投資建設電子級玻纖布擴建項目的議案》,同意全資子公司安徽金瑞電子玻纖有限公司使用自籌資金2億元投資建設年產6000萬米電子級玻纖布擴建項目。項目原計劃於2020年1月底前進行試生產,後因項目審批手續及市場行情原因公司延後了該項目的實施工作。
目前該項目已完成了主體廠房的建設,下一步將進行設備的安裝及調試,預計在2022年下半年投產。公司將持續關注項目的進展情況,及時披露進展情況。敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.